Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Deviations in human gut m… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Deviations in human gut microbiota: a novel diagnostic test for determining dysbiosis in patients with IBS or IBD

Artikel i vetenskaplig tidskrift
Författare C. Casen
H. C. Vebo
M. Sekelja
F. T. Hegge
M. K. Karlsson
E. Ciemniejewska
S. Dzankovic
C. Froyland
R. Nestestog
L. Engstrand
P. Munkholm
O. H. Nielsen
G. Rogler
Magnus Simrén
Lena Öhman
M. H. Vatn
K. Rudi
Publicerad i Alimentary Pharmacology & Therapeutics
Volym 42
Nummer/häfte 1
Sidor 71-83
ISSN 0269-2813
Publiceringsår 2015
Publicerad vid Institutionen för biomedicin, avdelningen för mikrobiologi och immunologi
Institutionen för medicin, avdelningen för invärtesmedicin och klinisk nutrition
Sidor 71-83
Språk en
Länkar dx.doi.org/10.1111/apt.13236
Ämnesord IRRITABLE-BOWEL-SYNDROME, FECAL MICROBIOTA, INTESTINAL MICROBIOTA, CROHNS-DISEASE, TRANSPLANTATION, DEPRESSION, DIVERSITY, CHILDREN, THERAPY, ADULTS, Gastroenterology & Hepatology, Pharmacology & Pharmacy
Ämneskategorier Gastroenterologi

Sammanfattning

BackgroundDysbiosis is associated with many diseases, including irritable bowel syndrome (IBS), inflammatory bowel diseases (IBD), obesity and diabetes. Potential clinical impact of imbalance in the intestinal microbiota suggests need for new standardised diagnostic methods to facilitate microbiome profiling. AimTo develop and validate a novel diagnostic test using faecal samples to profile the intestinal microbiota and identify and characterise dysbiosis. MethodsFifty-four DNA probes targeting 300 bacteria on different taxonomic levels were selected based on ability to distinguish between healthy controls and IBS patients in faecal samples. Overall, 165 healthy controls (normobiotic reference collection) were used to develop a dysbiosis model with a bacterial profile and Dysbiosis Index score output. The model algorithmically assesses faecal bacterial abundance and profile, and potential clinically relevant deviation in the microbiome from normobiosis. This model was tested in different samples from healthy volunteers and IBS and IBD patients (n=330) to determine the ability to detect dysbiosis. ResultsValidation confirms dysbiosis was detected in 73% of IBS patients, 70% of treatment-naive IBD patients and 80% of IBD patients in remission, vs. 16% of healthy individuals. Comparison of deep sequencing and the GA-map Dysbiosis Test, (Genetic Analysis AS, Oslo, Norway) illustrated good agreement in bacterial capture; the latter showing higher resolution by targeting pre-determined highly relevant bacteria. ConclusionsThe GA-map Dysbiosis Test identifies and characterises dysbiosis in IBS and IBD patients, and provides insight into a patient's intestinal microbiota. Evaluating microbiota as a diagnostic strategy may allow monitoring of prescribed treatment regimens and improvement in new therapeutic approaches.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?